The research news is interesting but we need to have realistic expectations regarding price and availability. All products, even HM, have to obey the law of supply and demand.
TRC is a bespoke product not mass production of identical doses, and this will limit supply. Demand, though, will be enormous. Initially, Intercytex won’t be able to supply everyone who wants HM. They can’t supply more than they can produce. They will have to match supply to demand by price or waiting list. There’s no other way of doing it.
Intercytex, or Aderans for that matter, will not set a low price and have to manage an enormous waiting list, probably stretching out years, when they can command a higher price for the product. They could launch in only one country but that is just another form of waiting list.
Initially, Intercytex could produce, say, 10,000 treatments a year. If price wasn’t an issue, demand would be in the tens of millions. Even if they could produce 100,000 treatments a year and demand was from only 1,000,000 men, that’s still a fair old waiting list. First off, you can easily imagine it will be high price and waiting list.
Gradually, more supply will come on stream. Intercytex and Aderans may open production facilities in Asia or US, and new players may arrive. The price and waiting list will then fall. That’s a few more years away though.
We’re all interested in how the research is going but production capacity is at least as important